A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants
Study Details
Study Description
Brief Summary
The primary objective of this study is to evaluate safety and tolerability data when SRSD107 is administered as single and multiple SC injections to healthy participants. This information, along with PK/PD data, will help establish the appropriate doses and dosing regimen for future studies in patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA). The antisense strand (AS) is specifically designed to mimic human factor XI (FXI) messenger ribonucleic acid (mRNA). By selectively modulating coagulation through inhibition of FXI, SRSD107 can prevent thromboembolic events without increasing the risk of bleeding.
This study will be a phase 1, randomized, double blind, placebo controlled, single and multiple ascending dose study conducted in two parts. Part A will comprise a single dose, sequential group design. A total of 40 participants will be studied in 5 groups (Groups A1 to A5), with each group comprising 8 participants. In each group, 6 participants will receive SRSD107 and 2 participants will receive placebo. Part B will comprise a multiple dose, sequential group design. A total of 24 participants will be studied in 3 groups (Groups B1 to B3), with each group comprising 8 participants. In each group, 6 participants will receive SRSD107 and 2 participants will receive placebo.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SRSD107 SRSD107 for subcutaneous (s.c.) injection Group A1, 15mg, single dose Group A2, 45mg, single dose Group A3, 120mg, single dose Group A4, 240mg, single dose Group A5, 450mg, single dose Group B1, 45mg per dose, 90mg multi dose Group B2, 120mg per dose, 240mg multi dose Group B3, 225mg per dose, 450mg multi dose |
Drug: SRSD107
SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
|
| Placebo Comparator: Placebo Sodium chloride for subcutaneous (s.c.) injection |
Drug: Placebo
Sodium chloride
|
Outcome Measures
Primary Outcome Measures
- Proportion of adverse events (AEs) [up to 168 days post last dose]
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
- Proportion of Serious Adverse Events (SAEs) [up to 168 days post last dose]
A serious AE (SAE) is defined as any untoward medical occurrence that at any dose either: results in death is life threatening requires inpatient hospitalization or prolongation of existing hospitalization results in persistent or significant disability/incapacity (disability is defined as a substantial disruption of a person's ability to conduct normal life functions) results in a congenital anomaly/birth defect results in an important medical event (see below).
Secondary Outcome Measures
- Cmax [Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31]
Maximum observed plasma concentration
- tmax [Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31]
Time to maximum plasma concentration
- t1/2 [Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31]
Plasma half-life
- AUC [Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31]
Area under the plasma concentration-time curve from 0 to infinity
- CL/F [Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31]
Apparent total clearance
- Effect of SRSD107 on circulating FXI Levels [up to 168 days post last dose]
Determination of % Lowering of FXI to Baseline FXI Level
- Effect of SRSD107 on coagulation [up to 168 days post last dose]
Determination of % APTT to baseline APTT
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Body mass index between 18.0 and 32.0 kg/m2, inclusive.
-
In good health, based on no clinically significant findings from medical history, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations.
-
Activated partial thromboplastin time and PT within the normal range.
-
Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
-
Able to understand and willing to sign an ICF and to abide by the study restrictions.
Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
-
History or evidence of any abnormal bleeding or coagulation disorder; or evidence of coagulopathy, prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombus formation; or a history of spontaneous bleeding.
-
Evidence of an active or suspected cancer, or a history of malignancy, within 5 years prior to screening. Nonmelanoma skin cancer, curatively treated localized prostate cancer, or other carcinoma in situ are not exclusionary, providing that they did not require systemic therapy and are considered cured.
-
Acute of febrile illness within 7 days prior to dose administration or evidence of active infection.
-
Any major surgery within 3 months prior to screening or plan to have any surgery during the study.
-
History of clinically significant hypersensitivity, intolerance, or allergy to any drug compound, oligonucleotide, GalNAc, food, or other substance, as determined by the investigator (or designee).
-
Confirmed systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.
-
QT interval corrected for heart rate using Fridericia's method (QTcF) >450 ms in males or >470 ms in females confirmed by repeat measurement.
-
White blood cell count <3.5 × 109/L, platelets <100 × 109/L, or hemoglobin below the lower limit of normal.
-
Alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, alkaline phosphatase, or total bilirubin >1.5 × the upper limit of normal (ULN).
-
Estimated glomerular filtration rate <80 mL/min/1.73m2, as calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration equation.
-
Positive hepatitis panel and/or positive human immunodeficiency virus test.
-
Positive pregnancy test at screening or check in.
-
Receipt of blood products within 2 months prior to check in.
-
Loss of >500 mL whole blood or donation of blood products within 1 month prior to screening.
-
History of intolerance to SC injections, or scarring (eg, from surgical procedures or burns) in areas when SC dose administration may occur.
-
Participants who, in the opinion of the investigator (or designee), should not participate in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Linear Clinical Research | Perth | Other (Non U.s.) | Australia |
Sponsors and Collaborators
- Sirius Therapeutics Co., Ltd.
Investigators
- Study Director: Qiuyue Qu, Sirius Therapeutics Co., Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SRSD107 101